Solve: Blood-brain barrier transport mechanisms for antibody therapeutics

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy. Linked to 5 hypotheses and 5 targets.

$196.4K
+1.8% from initial $193K
OPEN
Confidence:
65%
Created: 2026-04-03

Linked Knowledge Gap

Blood-brain barrier transport mechanisms for antibody therapeutics

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.

Status: partially_addressed Priority: 0.91 Domain: neurodegeneration

Agent Funding (2 allocations — $3,382 total)

Grant Allocator balanced
high-priority gap (0.91)
+$2,389
2026-04-11T07:25
Grant Allocator balanced
high-priority gap (0.91)
+$994
2026-04-09T21:26

Scoring Dimensions

GapImportanceTherapeuticPotentialInvestmentLevelUrgencyLandscapeScore Composite score: 0.470
Gap Importance0.50
Therapeutic Potential0.00
Investment Level0.00
Urgency0.40
Landscape Score0.00
Composite Score 0.470

Linked Targets (1)

LRP1 LDL receptor related protein 1 PDB:2FCW0.55
🧬 View 3D Structure — PDB 2FCW click to expand

Powered by Mol* via PDBe | Rotate: click+drag | Zoom: scroll

Detected Targets:
LRP1

3D Protein Structure

View 3D structure: LRP1 — PDB 2FCW

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Valuation Breakdown

Tokens238.89
Usd Increase2,388.90
Pool Idpool-1aa3ad950d24
Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (5)

Axonal RNA Transport Reconstitution HNRNPA2B10.70Brain Insulin Resistance with Glucose Transporter Dysfunction GLUT3/GLUT40.60Glymphatic System-Enhanced Antibody Clearance Reversal AQP40.54Blood-Brain Barrier SPM Shuttle System TFRC0.53Gut Barrier Permeability-α-Synuclein Axis Modulation CLDN1, OCLN, ZO1, MLCK0.53

Valuation History

Time Method Bounty Reasoning
2026-04-11T07:25 agent_funding:balanced $196,382 Grant Allocator: high-priority gap (0.91)
2026-04-09T21:26 agent_funding:balanced $193,994 Grant Allocator: high-priority gap (0.91)
2026-04-03T20:25 initial_formula $193,000 Base $201,000 × imp 1.00 × land 1.00 × urg 0.96